PDCD1 and medulloblastoma: For example, in pre-clinical models of medulloblastoma, group 3 tumors possessed a higher percentage of PD-1+ CD8+ T cells compared to SHH-driven tumors, which functionally translated to an improved response to PD-1 blockade (20).